Article

You have full text access to this OnlineOpen article

Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment

  1. M G Swain,
  2. M Maric

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510250206

Issue

Hepatology

Hepatology

Volume 25, Issue 2, pages 291–294, February 1997

Additional Information

How to Cite

Swain, M. G. and Maric, M. (1997), Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology, 25: 291–294. doi: 10.1002/hep.510250206

Author Information

  1. Liver Unit, Gastroenterology Research Group, University of Calgary, Alberta, Canada

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (175K)

References

  • 1
    Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12: 98–105.
    Direct Link:
  • 2
    Hart BL. Biological basis of the behaviour of sick animals. Neurosci Biobehav Rev 1988; 12: 123–127.
  • 3
    Kent S, Bluthe R-M, Kelley KW, Dantzer R. Sickness behaviour as a new target for drug development. TIPS 1992; 13: 24–28.
  • 4
    Jones EA. Fatigue associated with chronic liver disease: a riddle wrapped inside a mystery inside an enigma. Hepatology 1995; 22: 1606–1608.
  • 5
    Swain MG, Patchev V, Vergalla J, Chrousos GP, Jones EA. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 1993; 91: 1903–1908.
  • 6
    Swain MG, Marie M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioural responses in cholestatic rats: implications for cholestatic liver disease–related sickness behaviours. Hepatology 1995; 22: 1560–1564.
  • 7
    Sternberg EM, Glowa JR, Smith MA, Cologero AE, Listwak SJ, Aksentijevich S, Chrousos GP, et al. Corticotropin releasing hormone related behavioural and neuroendocrine responses to stress in Lewis and Fischer rats. Brain Res 1992; 570: 54–60.
  • 8
    Beam J, Wessely S. Neurobiological aspects of the chronic fatigue syndrome. Eur J Clin Invest 1994; 24: 79–90.
    Direct Link:
  • 9
    Bakheit AMO, Behan PO, Dinan TG, Gray CE, O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J 1992; 304: 1010–1012.
  • 10
    Calogero AE, Bagdy G, Szemeredi K, Tartaglia ME, Gold PW, Chrousos GP. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 1990; 126: 1888–1894.
  • 11
    Weiss JM, Simson PG, Hoffman LJ, Ambrose MJ, Cooper S, Webster A. Infusion of adrenergic receptor agonists and antagonists into the locus coeruleus and ventricular system of the brain effects on swim-motivated and spontaneous motor activity. Neuropharmacology 1986; 25: 367–384.
  • 12
    Cameron GR, Oakley CL. Ligation of the common bile duct. J Pathol Bacteriol 1932; 35: 769–798.
    Direct Link:
  • 13
    Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Carbon Tetrachloride. New York: Appleton-Century-Crofts, 1979: 198–217.
  • 14
    Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 226: 730–732.
  • 15
    Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, et al. Pharmacological characterization of LY293284: a 5HT1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 1994; 270: 1270–1281.
  • 16
    Burnet PWJ, Mefford IN, Smith CC, Gold PW, Sternberg EM. Hippocampal 8-[3H] Hydroxy-2-(Di-n-propylamino) tetralin binding site densities, serotonin receptor (5-HT1A) messenger ribonucleic acid abundance and serotonin levels parallel the activity of the hypothalamopituitary-adrenal axis in rat. J Neurochem 1992; 59: 1062–1070.
    Direct Link:
  • 17
    Swain MG, Marie M, Carter L. Defective interleukin-1-induced ACTH release in cholestatic rats: impaired hypothalamic PGE2 release. Am J Physiol 1995; 268: G404–G409.
  • 18
    Kennett GA, Dourish CT, Curzon G. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol 1987; 134: 265–274.
  • 19
    David A. Postviral fatigue syndrome and psychiatry. Br Med Bull 1991; 47: 966–988.
  • 20
    Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue and quality of life in primary biliary cirrhosis [Abstract]. Hepatology 22; 1995: 108A.
  • 21
    Roth BL. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psych 1994; 6: 67–78.
  • 22
    Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Rev 1994; 46: 158–201.
  • 23
    Curzon G. 5-Hydroxytryptamine and corticosterone in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 305–310.
  • 24
    Farrell RJ, Khan I, Maloney M, Farrell J, McDonald GSA, Keeling PWN. Correlation between symptoms, aminotransferases and liver histology in IVDA hepatitis C patients [Abstract]. Gastroenterology 1995; 108: A1064.
  • 25
    Kirby LG, Allen AR, Lucki I. Regional differences in the effects of forced swimming on extracellular levels of 5-hydroxytryptamine and 5-hydroxy-indoleactic acid. Brain Res 1995; 682: 189–196.
  • 26
    Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis [Letter]. N Engl J Med 1994; 330: 1540.
  • 27
    Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992; 597: 331–338.
  • 28
    Jones EA, Bergasa NV. Hypothesis–the pruritus of cholestasis: from bile acids to opiate antagonists. Hepatology 1990; 11: 884–887.
    Direct Link:
  • 29
    Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993; 74: 3006–3012.
  • 30
    Bailey SP, Davis JM, Ahlborn EN. Effect of increased brain serotonergic activity on endurance performance in the rat. Acta Physiol Scand 1992; 145: 75–76.
    Direct Link:
  • 31
    Wilson WM, Maughn RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992; 77: 921–924.
Get PDF (175K)